INTRODUCTION
It has been more than five decades since Billingham formulated the three requirements for the development of GVHD: the graft must contain immunologically competent cells; the recipient must express tissue Ag that are not present in the transplant donor; and the recipient must be incapable of mounting an effective response to eliminate the transplanted cells. 1 Over these years and despite many advances in donor selection, infection prophylaxis and immunosuppressant therapy, GVHD remains the major complication of allo-SCT and results in significant morbidity and mortality. 2 Clinical manifestations of GVHD depend upon the degree of donor-host histocompatibility and graft alloreactivity to major host Ag. Epithelial cells of the skin and mucous membranes, biliary ducts and intestinal tract crypts are the primary tissue systems damaged during the pathobiological course of GVHD, although many other organs in the body may also be affected. 3 Acute gut GVHD (G-GVHD) is frequently the most severe and difficult to treat and may involve any location throughout the gastrointestinal tract with nausea, vomiting, crampy abdominal pain, distention, paralytic ileus, intestinal bleeding and voluminous, often bloody diarrhea. 4 Acute upper G-GVHD usually presents with anorexia, dyspepsia, nausea and vomiting and may respond better to therapy compared with lower G-GVHD. 5 Whether GVHD affects the lower or upper part of the gastrointestinal tract, it is frequently the most severe and difficult to treat compared with skin only GVHD. However, it is unknown if skin involvement with G-GVHD has any prognostic significance. This may be useful for therapeutic choices and balancing effective anti GVHD therapy and treatments side effects.
PATIENTS AND METHODS Patients
The study was approved by our institutional research ethics board. The health records of children who received allo-SCT between January 2000 and December 2009 were reviewed. The diagnosis of acute G-GVHD may be made based on the clinical criteria of nausea, vomiting and the volume of diarrhea using the consensus criteria of the acute GVHD scoring system. 6 However, these symptoms may also be attributable to chemoradiation toxicity, medication side effects, or a variety of bacterial, fungal, viral and parasitic infections making the differential diagnosis of these symptoms very broad. 7 Therefore, only patients who had endoscopy or colonoscopy and biopsy for G-GVHD were included in the study. Patients' demographics were collected and included: age, gender, diagnosis, conditioning regimen, donor and stem cell source and GVHD prophylaxis. Acute GVHD was scored weekly by a dedicated SCT physician based on the acute GVHD consensus criteria. For skin involvement, a stage 2 (25-50% of body surface area) or more was required to characterize the patient as having skin involvement. Two groups were identified, a gut only G-GVHD group and a combined group of gut and skin GVHD (GS-GVHD). Outcome data were collected and included: neutrophil engraftment, gastrointestinal biopsy results including virology immunohistochemistry, GVHD grades, time of starting the GVHD therapy, response to the therapy, causes of death and OS.
Conditioning regimen, GVHD prophylaxis/treatment and supportive care
All patients were nursed in protective isolation in single rooms with highefficiency particulate air filters. All patients received fluconazole for fungal prophylaxis, ganciclovir for CMV prophylaxis if the donor or recipient serostatus for CMV was positive (2000-2004) and a pre-emptive ganciclovir strategy based on weekly CMV PCR testing from 2004 onwards. Pneumocystis jiroveci pneumonia prophylaxis was given for at least 6 months following SCT. Pneumococcal prophylaxis with penicillin continued for at least 1 year following HSCT or until vaccinated with pneumococcal vaccine. Other prophylactic antibiotics and oral decontamination regimens were not used. Fever during the neutropenic phase was treated with broad-spectrum antibiotics and amphotericin or caspofungin empirically. Blood products were transfused to maintain Hb concentration470 mg/L and platelet counts of 20 000/mm 3 . CMV-negative patients were transfused with CMV-negative blood products and all blood products were irradiated. Neutrophil engraftment was defined as the first 1 of three consecutive days, following the neutrophil nadir, of ANC 40.5 Â 10 9 /L. Primary graft failure was defined in patients surviving beyond day þ 28 ( þ 35 for cord stem cells) as failure to attain an ANC 40.5 Â 10 9 /L before death or receipt of a second graft. When BU was used as part of the condition regimen, it was given i.v. with dose adjustment based on area under the curve pharmacokinetics study and when TBI was used as a part of the conditioning regimen, it was given in six fractions of 200 cGy twice a day for 3 days (total 1200 cGY). Standard GVHD prophylaxis was either with CsA and four doses of MTX at 10 mg/m 2 given at day þ 1, 3, 6 and 11 for unrelated donors or related donors for non-malignant diagnosis or day þ 1, 3 and 6 for related donors with a malignant diagnosis. CSA and methylprednisone (MP) at 2 mg/kg/day starting at day þ 5 following SCT was given when utilizing cord progenitor stem cells. Patients not tolerating CSA or MP received tacrolimus instead of CSA and mycophenolate mofetil instead of MP. Acute G-GVHD grade II and more was treated. First line GVHD therapy was MP at 2 mg/kg/day divided into two doses per day given i.v. GVHD treatment for those who were already on 2 mg/kg/day MP as part of GVHD prophylaxis was either escalating MP dose to 30 mg/kg/day divided into two doses per day for 3 days or adding another agent such as daclizumab. Response was defined as resolution of gut symptomatology with stage zero (grade 1) G-GVHD score based on consensus criteria. Steroid reduction was slow and followed weekly or biweekly dose reduction over 6-8 weeks. Daclizumab was used as a second line therapy for steroid refractory GVHD (defined as progression or no response after 5 days of at least 2 mg/kg/day MP) with a scheduled dosing of 1 mg/kg/day at day 1, 4, 8, 15 and 22 associated with a faster wean of steroids (1-2 weeks). 8 The decision to escalate GVHD therapy to a second line agent was based on gut symptoms and diarrhea volume and not on skin, that is, all patients, even those with skin involvement, were treated as primary G-GVHD and response was assessed based on gut response. Upper and lower gut endoscopy/colonoscopy and biopsy was requested in the event of a clinical suspicion of acute G-GVHD. The endoscopy/ colonoscopy and biopsy procedures were performed by an experienced gastroenterology consultant staff under general anesthesia. Histological confirmation for G-GVHD was based on the pathological report examining intestinal mucosa, cellular infiltration and apoptotic bodies. All surgical pathology specimens were tested by immunohistochemistry for viruses such CMV, Epstien-Barr virus and adenovirus.
Statistical analysis
The SAS software (version 9.2; SAS Institute Inc., Cary, NC, USA) was used to perform statistical analyses. Time to event and the probability of EFS for different end points was determined using Kaplan-Meier curves. Time zero was defined as the SCT date. The log-rank test was used to assess the differences between survival curves for the two groups of patients, G-GVHD and GS-GVHD. Differences in continuous outcomes between the two groups were compared using the Wilcoxon rank-sum test. Categorical variables were compared using the w 2 test or Fisher's exact test as appropriate. The cumulative incidence of relapse and transplant related mortality (TRM) was estimated taking into account competing risks of other events. A multivariate survival model was performed taking into account different variables effect on survival.
RESULTS
From January 2000 to December 2009, 450 children between the ages of 0-18 years underwent allo-SCT. Seventy-nine (17.5%) patient underwent endoscopy or colonoscopy and biopsy for G-GVHD. Forty-nine patients had isolated G-GVHD and 30 had combined, GS-GVHD. Patients demographics are detailed in Table 1 . There were no statistically significant differences in patients demographics between the two groups apart from more cord progenitor stem cells were used in the G-GVHD group (35%) vs 10% in the GS-GVHD (P ¼ 0.048). Table 2 details the outcome of both groups. Interestingly, liver involvement was more frequent when G-GVHD has extended to the skin (P ¼ o0.0001). Higher grade acute GVHD (grade III-IV) was more common among GS-GVHD group compared with G-GVHD group (66% vs 30% P ¼ 0.01). Between the two groups there were no differences in biopsy results whether it was positive or negative, viral staining results and time of initiating anti GVHD therapy. Overall response to GVHD therapy was similar in both the groups (83% vs 88% P ¼ 0.7). There was, however, more likelihood to start second line GVHD therapy in the GS group (P ¼ 0.003) mainly due to poor initial response to first line therapy. However, the decision to start a second line therapy was based on G-GVHD response and was uniform to both groups. For the outcome analysis, two sets of analysis were performed; First analysis was performed taking into account all patients (biopsy result positive and biopsy result negative in each group), intention to treat analysis. The second analysis was the outcome of only biopsy positive patients in each group. For the first set of the analysis (whole-group) the possibility of relapse of malignant disease was similar in both groups, however, there was a statistically significant increase in the incidence of GVHD related TRM in the G-GVHD group compared with the GS-GVHD group leading to a superior outcome for those with skin involvement (79% vs 49% P ¼ 0.02). This significantly better outcome for GS-GVHD was also evident in the second set of outcome analysis comparing only biopsy positive patients in each group (P ¼ 0.04) ( Figure 1 ) and a significant increase in TRM in the G only group (P ¼ 0.04) (Figure 2 ). Five patients died from TRM in the GS-GVHD group (all five patients had a positive biopsy results) while 18 patients died from TRM in the G-GVHD group (14/18 patients had positive biopsy results). Causes of TRM were as follows; progressive severe GVHD, n ¼ 8; respiratory related deaths, n ¼ 7 (respiratory failure 2, bronchiolitis obliterans with organized pneumonia 3, bronchiolitis obliterans 1 and parainfluenza type 3 lower respiratory tract infection 1); sepsis with multi organ failure n ¼ 5; disseminated adeno virus infection n ¼ 1; encephalopathy n ¼ 1, and one patient died from a sudden cardiac arrest. This patient has received a cardiac transplant in the neonatal period and 3 years later received an allo-SCT for T-cell leukemia. In a multivariate survival model taking into accounts multiple variables effect on survival, only skin involvement had a significant positive impact on outcome (Table 3) .
DISCUSSION
In this study, we found that acute G-GVHD was associated with worse prognosis compared with combined GS-GVHD due to Gut and skin GVHD A Gassas et al increased risk of TRM. Although we cannot explain the pathobiological reason for this observation, this knowledge is helpful to guide future therapies, supportive care and estimate prognosis for children with acute G-GVHD. A potential possible explanation for children with GS-GVHD in our study having a better prognosis compared with G-GVHD was the fact that children with skin involvement may have started GVHD therapy earlier due to visible skin rash. However, in our study this was not the case. All patients were primarily G-GVHD and there were no differences between the two groups in terms of therapy initiation, whether it started before or after biopsy or not started at all. There was, however, difference in escalating GVHD for the GS group based on a uniform criteria of steroid refractoriness. Nonetheless, the same criteria were applicable to both groups. Furthermore, escalating therapy to a second line level was based on clinical non response for the gut component of GVHD and not skin. Interestingly, overall response rate to GVHD therapy and malignant disease relapse in both the groups were similar.
Barker et al. 9 examined gut complications following SCT in a heterogeneous group of 132 pediatric patients that underwent 142 transplants. Acute GVHD was most commonly diagnosed in conjunction with skin manifestations. A combination of skin and gut involvement accounted for 59/65 of the reported cases. It was rare to diagnose only G-GVHD (2/65). This was likely due to the ease of diagnosing skin compared with intestinal manifestations of acute GVHD. However, GvHD diagnosis was based on clinical criteria without endoscopy and biopsy. Our study demonstrated that, if gut endoscopy and biopsy was performed to supplement the clinical suspicion of G-GVHD, the incidence of isolated G-GVHD is not that rare, 49/79 of our patients had isolated G-GVHD. To supplement our results, in a prospective study of SCT patients with diarrhea, both upper endoscopy and sigmoidoscopy with biopsies were performed in 24 patients, all of whom had gut symptoms, mucosal gut biopsy was positive for GVHD in 14/24 patients whose skin biopsy was negative. 10 Two thirds of patients with GS-GVHD had high grade (III-IV) GVHD compared with only 30% in the G only group. This has led to inadequate response to initial therapy in the GS-GVHD group with higher likelihood of adding a second agent for the GS group. However, the overall response in both groups was similar and had no relation to GVHD grade. This is consistent with the results of a very large report of 443 children and adults post SCT with acute GVHD where complete and partial response to acute GVHD therapy was independent of GVHD grade using the three commonly used grading systems, Minnesota, Consensus and IBMTR.
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TRM was unusually high in the G-GVHD group compared with GS-GVHD. While it is known that acute GVHD increases TRM due to infections and other complications, it is uncertain why it was increased in the gut only group in our study. One possible explanation could be that more cord progenitor stem cells were utilized in the G-GVHD group (35% vs 10% in GS-GVHD). Cord stem cells are known to cause delayed engraftment and delayed immune recovery with increased risk of infections, however, this is normally balanced against the less severe form of acute GVHD associated with cord stem cells leading to similar OS compared with BM stem cells. 12 Our study has an important strength of including only children with gastrointestinal scope and gut biopsy for GVHD. This ensures fair comparison between the G and GS-GVHD groups. Furthermore, we have performed a second set of analysis taking into account only biopsy positive patients in each group and demonstrated the same results, higher TRM in the G-GVHD compared with GS-GVHD. The intention to treat analysis that took into account all patients, biopsy result positive or negative, was important as in some patients antiGVHD therapy was started before the biopsy and in other patients antiGVHD therapy continued despite a negative biopsy as the clinical picture was typical of gut GVHD. Our main study limitation is the retrospective nature and the modest sample size of 79 patients. Further, larger studies are required to further enhance our understanding about acute GVHD pathobiology and reasons to extend beyond the gastrointestinal tract and its effect on the ultimate prognosis.
In summary, our study suggests that there is a higher TRM associated with isolated acute G-GVHD compared with combined GS-GVHD. This may have important treatment and prognosis implications for children following SCT with acute G-GVHD. Further research is required to enhance our understanding about G-GVHD and factors or serum markers that lead to its extension beyond the gut.
